Orchid Pharma opened lower at ₹975.10, compared with its previous close of ₹979.35. During today's session, the stock has traded between ₹947.00 and ₹981.75, with an average traded price of ₹961.60. It is currently showing a downward intraday trend.
An investment of ₹10,000 made 5 years ago in Orchid Pharma is now worth
₹ 21,867.00
giving a profit of
₹ 11,867.00 (118.67%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-19.40 (-1.98%)
Day High
₹981.75
Day Low
₹947.00
Day Open
₹975.10
Prev Close
₹979.35
Volume
50,365
Value Traded
₹4.84 Cr
1W Return
-0.62%
1M Return
-4.30%
3M Return
-5.19%
6M Return
71.82%
1Y Return
28.75%
Market Cap (₹ Cr.)
5,749
PE Ratio
546.90
PB Ratio
3.75
Dividend Yield
-
ROE
0.68%
ROCE
1.10%
Book Value (₹)
261.22
Face Value (₹)
10.00
EPS (TTM)
0.54
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-0.62%
6 Week
-
1 Month
-4.30%
3 Month
-5.19%
9 Month
33.07%
Orchid Pharma adopts revised FY26 financials at 33rd AGM
Orchid Pharma adopted revised standalone and consolidated financial statements for FY26 at its 33rd AGM. Consolidated auditor's report contained qualifications; standalone report remained unqualified. Mridul Dhanuka reappointed as Whole-Time Director; Arjun Dhanuka appointed as new Whole-Time Director. Approval granted for material related party transactions with Otsuka Chemical (India) Private Limited.
14 days agoOrchid Pharma lists 4.45 crore equity shares on NSE and BSE
Orchid Pharma listed 4,45,86,052 equity shares on NSE and BSE from September 23, 2026. Shares were allotted under a scheme of amalgamation approved by the NCLT, Chennai Bench. The company filed intimation under Regulation 30 of SEBI Listing Regulations.
20 days agoOrchid Pharma buys Kancheepuram land, ends DBS Bank lease
Orchid Pharma acquired land in Kancheepuram District, Tamil Nadu. Lease arrangement with DBS Bank India Limited formally concluded. Company secured permanent ownership rights over the property.
20 days agoOrchid Pharma schedules Mumbai investor roadshow for late September
Orchid Pharma schedules an investor roadshow in Mumbai from September 28 to 30, 2026. Whole Time Director Mridul Dhanuka will lead the physical group meets. The company filed the intimation under SEBI LODR Regulation 30. No unpublished price-sensitive information will be shared during the event.
22 days agoOrchid Pharma schedules AGM for Sep 29; seeks approval for ₹400 crore Otsuka RPT
Orchid Pharma schedules its 33rd AGM for September 29, 2026. Shareholders to approve ₹400 crore RPT limit with Otsuka for FY27. Arjun Dhanuka appointed as Whole-Time Director until 2031. E-voting window runs from September 26 to September 28, 2026.
1mo agoOrchid Pharma files FY26 BRSR report; pharma makes 97% of turnover
Orchid Pharma filed its FY26 BRSR with NSE and BSE. Pharma manufacturing contributes 97% of total turnover. Report prepared on a standalone basis for FY ended March 2026. No external assurance provider engaged for this report.
1mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,770.70 | +0.61% | ₹4,24,850.24 | 34.83 | +5.97% | |
| ₹9,285.00 | -1.50% | ₹2,46,487.58 | 85.12 | +43.41% | |
| ₹4,642.90 | -0.84% | ₹1,76,600.99 | 82.55 | +31.42% | |
| ₹1,132.50 | -0.17% | ₹1,12,967.31 | 24.74 | +14.00% | |
| ₹2,059.40 | -0.47% | ₹1,11,271.90 | 102.63 | +134.89% | |
| ₹1,329.60 | +1.40% | ₹1,07,412.86 | 31.62 | -14.87% | |
| ₹1,240.00 | +0.86% | ₹1,03,500.36 | 32.26 | -1.93% | |
| ₹2,372.00 | -1.17% | ₹97,974.30 | 47.92 | -3.57% | |
| ₹1,684.60 | -1.31% | ₹96,928.16 | 26.40 | +49.04% | |
| ₹1,953.60 | +0.96% | ₹89,336.17 | 16.03 | -0.29% | |
| ₹2,265.30 | -0.78% | ₹63,932.35 | 35.82 | +16.81% | |
| ₹5,250.00 | +0.86% | ₹62,771.63 | 28.34 | -3.75% |
An investment of ₹10,000 made 5 years ago in Orchid Pharma is now worth
₹ 21,867.00
giving a profit of
₹ 11,867.00 (118.67%)
Note: Past profits do not guarantee future returns.
